Ensuring Integrity of the Medicaid Drug Rebate Program

Although the Medicaid Drug Rebate Program has generated substantial savings, persistent drug misclassification and ambiguous price-reporting rules have led to billions in unpaid rebates. The authors conclude that CMS’s 2024 final rule improves program oversight, but stronger enforcement and auditing practices are needed to safeguard the integrity of the program.